GlobeNewswire·Nov 13, 2026, 4:02 PM ET

TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

TRex Bio reported positive Phase 1a topline results for TRB-061 in healthy volunteers, demonstrating safety, proof of mechanism, & selection of doses for the ongoing Phase 1b trial in atopic dermatitis.
Topline data from the TRB-061 Phase 1b trial in atopic dermatitis patients is expected in mid-2027.
TRB-071, a CD30 agonist, is advancing through IND-enabling studies with a Phase 1 trial initiation expected in the first half of 2027.
TRB-051, a partnered program with Eli Lilly, is scheduled for a Phase 2a clinical trial in lupus with cutaneous involvement.
TRex Bio completed a $133.5 million IPO in October 2026, generating approximately $119.0 million in net proceeds & extending its cash runway into the second half of 2029.
Cash, cash equivalents, & marketable securities totaled $78.2 million as of September 30, 2026, excluding the October 2026 IPO proceeds.
Research & development expenses were $11.4 million for the third quarter of 2026, driven by higher clinical trial costs for TRB-061 & preclinical activities for TRB-071.
General & administrative expenses increased to $2.5 million in the third quarter of 2026 due to higher personnel costs & professional fees associated with operating as a public company.
The company reported a net loss of $13.2 million for the third quarter of 2026, compared to $7.9 million in the same period of 2025.